Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity

뉴스 본문을 불러오고 있어요.

Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity | 웨이프 WAPE

Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity

기사 요약

관련 종목

댓글 —